Recent progress of nanomedicine in managing dry eye disease

Advances in Ophthalmology Practice and Research · 5 authors, 2 centres

AI SUMMARY

FIDELITY 100%

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

This narrative review summarizes recent progress in nanomedicine for treating dry eye disease, highlighting that nanoformulations like nanoemulsions and liposomes offer improved drug delivery and some are already FDA-approved.

Full summary

547 CHARS

This narrative review discusses the potential of nanomedicine to address limitations of conventional dry eye disease (DED) treatments, such as low bioavailability and frequent administration. The review states that some nanoformulations have received FDA approval for DED, offering a partial solution to current treatment constraints. The authors conclude that while nanomedicine holds significant promise for DED therapy, challenges in clinical translation, commercialization, and further research on biocompatibility and pharmacokinetics remain.

STUDY TYPE

narrative_review

SPECIALTY

ophthalmology

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10864857

Recent progress of nanomedicine in managing dry eye disease

Advances in Ophthalmology Practice and Research

READ THE FULL PAPER

ABSTRACT

Background Dry eye disease (DED) is a commonly reported ocular complaint that has garnered significant attention in recent research. The global occurrence of DED ranges from 5% to 50%, impacting a substantial proportion of individuals worldwide with increasing frequency. Although topical administration remains the mainstream drug delivery method for ocular diseases, it suffers from drawbacks such as low bioavailability, rapid drug metabolism, and frequent administration requirements. Fortunately, the advancements in nanomedicine offer effective solutions to address the aforementioned issues and provide significant assistance in the treatment of DED. Main text DED is considered a multifactorial disease of the ocular surface and tear film, in which the integrity of tear film function and structure plays a crucial role in maintaining the homeostasis of the ocular surface. The conventional treatment for DED involves the utilization of artificial tear products, cyclosporin, corticosteroids, mucin secretagogues, and nonsteroidal anti-inflammatory drugs. Furthermore, nanomedicine is presently a significant field of study, with numerous clinical trials underway for various nanotherapeutics including nanoemulsions, nanosuspensions, liposomes, and micelles. Notably, some of these innovative nanoformulations have already received FDA approval as novel remedies for DED, and the advancement of nanomedicine is poised to offer enhanced prospects to solve the shortcomings of existing treatments for DED partially. Conclusions This article provides an overview of the latest advancements in nanomedicine for DED treatment, while the field of DED treatment is expected to witness a remarkable breakthrough shortly with the development of nanomedicine, bringing promising prospects for patients worldwide suffering conditions.

CITATION EXPORT

Zeen Lv, Su Li, Guixiang Zeng et al.. Recent progress of nanomedicine in managing dry eye disease. Advances in Ophthalmology Practice and Research. (2024). https://doi.org/10.1016/j.aopr.2024.01.008

AUTHORS

5 · 2 CENTRES

Zeen Lv, Su Li, Guixiang Zeng, Ke Yao, Haijie Han

aEye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases, Hangzhou, 310009, China
bDepartment of Pediatrics, No. 903 Hospital of PLA Joint Logistic Support Force, Hangzhou, 310013, China